The French pharma company in which previously invested Primo Capital attracted the resources of Institute for Follicular Lymphoma Innovation and of its current shareholders
Enterome, a French clinical-stage biopharmaceutical company that is developing OncoMimics first-in-class immunotherapies for cancer treatment, raised 19 million US Dollars from lead investor Institute for Follicular Lymphoma Innovation (9 million), Primo Capital sgr, SymBiosis, Seventure Partners, Lundbeckfonden BioCapital, Therapy Acceleration Program ofa Leukemia & Lymphoma Society (LLS TAP), and the other current shareholders (press release).
The firm will invest the raised proceeds in developing its clinical programme EO2463 for the treatment of indolent non-Hodgkin’s lymphoma (iNHL).
In 2020, the scaleup secured a Series E round of 46.3 million euros that SymBiosis, Takeda Pharmaceutical Company Limited, Seventure, Health for Life Capital, Xyence Capital (fka Principia), Omnes Capital, and Nestlé Health Science joined. Enterome parallely started to use a 40 million credit line that The European Investment Bank provided in 2018 (press release).
In 2018, the company closed a Series D round of 32 million in equity and attracted the resources of Xyence Capital, Seventure, Health for Life Capital, LundbeckFonden Ventures, Omnes Capital, Nestlé Health Science, and Bristol-Myers Squibb (see here a previous post by BeBeez).
In 2016, the startup secured a Series C round of 14.5 million euros from Seventure’s Health for Life Capital fund, Lundbeckfond Ventures, Nestlé Health Science, and other investors (press release). In 2014, Enterome raised 10 million through a Series B round that attracted the resources of Seventure and Omnes Capital (press release). In 2012, the company secured a Series A round of 5 million that Seventure and Lundbeckfond Ventures joined. Enterome previously received 1.5 million seed resources from Seventure and INRA Transfert (PrivateEquityWire).
